Durvalumab and focused ultrasound for liver cancer after chemo
Treatments studied
Part of Cancer clinical trials.
This trial tests combining two treatments: durvalumab (an immunotherapy drug) and histotripsy (a focused ultrasound that breaks down tumor tissue) for people with a type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if adding histotripsy after initial chemotherapy helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of liver cancer).
- Your cancer must have been controlled after at least 18 weeks of first-line standard treatment with gemcitabine, cisplatin, and durvalumab (an immunotherapy).
- Your tumor must be considered inoperable, or you must not be a candidate for surgery.
- You must be able to undergo general anesthesia and a liver biopsy.
- Your tumor must be suitable for histotripsy, a non-invasive focused ultrasound treatment that destroys tumor tissue.
- You must not have received prior local therapies (like ablation, embolization, or radiation) to the tumor being targeted.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This study tests a treatment for intrahepatic cholangiocarcinoma (a type of liver cancer) that can be surgically removed. It combines the usual chemotherapy drugs (cisplatin and gemcitabine) with the immunotherapy drug durvalumab, and compares it to the same regimen plus a targeted therapy called futibatinib, which works on specific genetic changes in the tumor. The goal is to see if adding the targeted therapy helps shrink the tumor before surgery and improves the outcome.
This trial tests adding a targeted chemo infusion into the liver's main artery to two immunotherapy drugs for liver cancer. It may help patients whose cancer has spread within the liver and can't be removed by surgery.
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
Phase 2 trial evaluating systemic therapy ± liver-directed RT for advanced intrahepatic cholangiocarcinoma, with broad eligibility for patients who have received at least 4 cycles of gem/cis/durvalumab.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.